Here's Why Shareholders Will Not Be Complaining About YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) CEO Pay Packet
May 22
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Pharma Industry Analysis
UpdatedMay 28, 2025
DataAggregated Company Financials
Companies40
- 7D6.2%
- 3M26.0%
- 1Y26.0%
- YTDn/a
In the last week, the Pharma industry is up 5.9%, with Hansoh Pharmaceutical Group up 6.8%. During this same period, the Hangzhou Jiuyuan Genetic Biopharmaceutical underperformed, falling 6.0%. This takes the industry's 12 month performance to a gain of 21%. Looking forward, earnings are forecast to grow by 11% annually.
Industry Valuation and Performance
Has the Hong Kong Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 28 May 2025 | HK$575.8b | HK$477.3b | HK$28.8b | 10.9x | 20x | 1.2x |
| Fri, 25 Apr 2025 | HK$511.2b | HK$467.0b | HK$28.6b | 10.4x | 17.9x | 1.1x |
| Sun, 23 Mar 2025 | HK$470.9b | HK$466.4b | HK$31.8b | 9x | 14.8x | 1x |
| Tue, 18 Feb 2025 | HK$432.7b | HK$463.0b | HK$31.9b | 8.6x | 13.6x | 0.9x |
| Thu, 16 Jan 2025 | HK$399.8b | HK$459.3b | HK$31.7b | 8x | 12.6x | 0.9x |
| Sat, 14 Dec 2024 | HK$440.1b | HK$462.0b | HK$31.9b | 8.3x | 13.8x | 1x |
| Mon, 11 Nov 2024 | HK$445.9b | HK$467.8b | HK$32.4b | 8.5x | 13.7x | 1x |
| Wed, 09 Oct 2024 | HK$517.7b | HK$475.5b | HK$33.0b | 9.3x | 15.7x | 1.1x |
| Fri, 06 Sep 2024 | HK$439.0b | HK$473.9b | HK$32.9b | 7.9x | 13.3x | 0.9x |
| Sun, 04 Aug 2024 | HK$419.0b | HK$464.3b | HK$32.9b | 7.4x | 12.7x | 0.9x |
| Tue, 02 Jul 2024 | HK$438.9b | HK$461.4b | HK$33.7b | 8.2x | 13x | 1x |
| Thu, 30 May 2024 | HK$460.1b | HK$463.6b | HK$33.9b | 8.4x | 13.6x | 1x |
| Sat, 27 Apr 2024 | HK$458.9b | HK$463.7b | HK$33.8b | 7.5x | 13.6x | 1x |
| Mon, 25 Mar 2024 | HK$460.5b | HK$469.8b | HK$32.8b | 7.8x | 14.1x | 1x |
| Wed, 21 Feb 2024 | HK$434.0b | HK$470.8b | HK$33.6b | 7.5x | 12.9x | 0.9x |
| Fri, 19 Jan 2024 | HK$433.0b | HK$471.4b | HK$33.6b | 7.1x | 12.9x | 0.9x |
| Sun, 17 Dec 2023 | HK$489.7b | HK$472.9b | HK$33.8b | 8x | 14.5x | 1x |
| Tue, 14 Nov 2023 | HK$491.5b | HK$469.1b | HK$31.9b | 7x | 15.4x | 1x |
| Thu, 12 Oct 2023 | HK$437.8b | HK$469.2b | HK$31.5b | 7x | 13.9x | 0.9x |
| Sat, 09 Sep 2023 | HK$421.1b | HK$468.7b | HK$31.5b | 6.8x | 13.4x | 0.9x |
| Mon, 07 Aug 2023 | HK$471.7b | HK$446.7b | HK$27.9b | 9x | 16.9x | 1.1x |
| Wed, 05 Jul 2023 | HK$507.6b | HK$446.1b | HK$27.8b | 9.8x | 18.3x | 1.1x |
| Fri, 02 Jun 2023 | HK$503.3b | HK$448.5b | HK$27.9b | 8.5x | 18x | 1.1x |
| Sun, 30 Apr 2023 | HK$570.4b | HK$453.4b | HK$28.5b | 8.9x | 20x | 1.3x |
| Tue, 28 Mar 2023 | HK$546.4b | HK$444.2b | HK$34.0b | 9.1x | 16.1x | 1.2x |
| Thu, 23 Feb 2023 | HK$606.0b | HK$444.8b | HK$35.2b | 11x | 17.2x | 1.4x |
| Sat, 21 Jan 2023 | HK$636.0b | HK$447.4b | HK$35.6b | 10.7x | 17.9x | 1.4x |
| Mon, 19 Dec 2022 | HK$617.3b | HK$441.6b | HK$34.7b | 10.6x | 17.8x | 1.4x |
| Wed, 16 Nov 2022 | HK$621.4b | HK$439.0b | HK$34.3b | 9.4x | 18.1x | 1.4x |
| Fri, 14 Oct 2022 | HK$512.8b | HK$514.0b | HK$39.0b | 7.8x | 13.1x | 1x |
| Sun, 11 Sep 2022 | HK$549.4b | HK$520.9b | HK$40.9b | 9.7x | 13.4x | 1.1x |
| Tue, 09 Aug 2022 | HK$593.4b | HK$512.4b | HK$51.8b | 8x | 11.4x | 1.2x |
| Thu, 07 Jul 2022 | HK$652.3b | HK$514.0b | HK$52.1b | 9.4x | 12.5x | 1.3x |
| Sat, 04 Jun 2022 | HK$565.5b | HK$515.9b | HK$52.1b | 8.8x | 10.8x | 1.1x |
Price to Earnings Ratio
10.8x
Current Industry PE
- Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 19.3x which is higher than its 3-year average PE of 14.8x.
- The industry is trading close to its 3-year average PS ratio of 1.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 18% per year over the last three years,
- Revenues have also declined 2.5% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Comparison
How does Hong Kong Pharma compare with similar industries?
| HK Market | 0.04% | |
| Healthcare | 3.13% | |
| Pharma | 6.20% | |
| Pharma | 6.20% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 867 China Medical System Holdings | HK$10.26 | 16.6% +HK$3.5b | 47.0% | PE14x | |
| 1093 CSPC Pharmaceutical Group | HK$6.82 | 4.6% +HK$3.4b | 1.0% | PE16.5x | |
| 3692 Hansoh Pharmaceutical Group | HK$25.65 | 1.4% +HK$2.1b | 57.7% | PE32x | |
| 1558 YiChang HEC ChangJiang Pharmaceutical | HK$14.64 | 10.4% +HK$1.2b | 50.9% | PE24.5x | |
| 2096 Simcere Pharmaceutical Group | HK$10.92 | 4.6% +HK$1.2b | 88.9% | PE33.8x |
